Answers are grounded in this paper and cite their sources.
This database study compares surveillance data on immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors to determine whether irAEs experienced during anti–PD-1 therapy correlate with tumor mutational burden across 18 cancer types.
No takes yet. Share an insight, caveat, or question.
Bomze et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: